Alexion (ALXN) and Celgene (CELG) Ratings Discusses as Revlimid Maintenance Has Last Showing Before Approval

In a Piper Jaffray research report this morning Alexion (NasdaqGS: ALXN) and Celgene (NasdaqGS: CELG) are both reviewed as they are awaiting approval for Soliris and Revlimid Maintenance respectively.

Alexion has an Overweight rating with a price target of $86.

Alexion closed Monday at $72.73.

Celgene has an Overweight rating with a price target of $81.

Celgene closed Monday at $60.96.